查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2014496

馬用藥品和補充劑市場：按產品類型、治療領域、給藥途徑、劑型、動物年齡層、最終用戶和分銷管道分類 - 全球市場預測（2026-2032 年）

Equine Pharmaceuticals & Supplements Market by Product Type, Therapeutic Category, Route Of Administration, Formulation, Animal Age Group, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025年，馬用藥品和補充劑市場價值10.3億美元，預計到2026年將成長至10.8億美元，複合年成長率為6.08%，到2032年將達到15.6億美元。

主要市場統計數據
基準年（2025 年） 10.3億美元
預計年份（2026年） 10.8億美元
預測年份（2032年） 15.6億美元
複合年成長率 (%) 6.08%

對馬匹治療市場進行概述，重點介紹臨床環境中的臨床重點、監管責任和相關人員的期望。

馬用藥品和營養補充劑領域需要採取重點突出的方法，以平衡臨床需求、監管要求和商業性可行性。日益複雜的治療方法、多樣化的終端使用者以及多種多樣的劑型，使得準確性、安全性和供應可靠性至關重要。獸醫和農場管理者需要能夠為成年馬、幼駒和一歲馬帶來可預測療效的產品，而研究機構和醫院則優先考慮循證配方和完善的不利事件監測。

技術創新、監管現代化和不斷發展的獸醫模式如何從根本上改變馬匹治療藥物的產品開發和交付。

馬匹治療領域正受到多種相互關聯的因素的影響而重塑，這些因素正在改變產品的研發、檢驗和交付方式。生技藥品和疫苗平台的進步使得更有針對性的預防方法成為可能，而對合理使用抗生素的需求則促使製劑研發人員和處方醫生轉向更精細的抗感染策略和替代性輔助療法。同時，數位健康工具和遠端醫療正在改變獸醫諮詢的頻率，並實現遠端監測，這正在影響產品的處方方式和用藥依從性的追蹤方式。

評估美國於 2025 年對馬用治療藥物價值鏈實施的關稅措施在營運、臨床和策略方面的多方面影響。

美國2025年實施的關稅措施對馬用藥品和補充劑相關企業的營運和策略決策產生了重大而多方面的影響。進口原料藥和成品的成本結構受到直接影響，迫使採購團隊加快重新評估供應商組合併選擇替代來源。實際上，為了降低未來的政策風險，本地採購、庫存緩衝以及在某些情況下將關鍵生產流程遷回或近岸外包變得更加重要。

可操作的細分資訊揭示了產品類型、治療分類、分銷管道、給藥途徑、最終用戶、配方和年齡層如何影響臨床應用。

在馬匹治療領域，細分是實現實際差異化的最直接方法。綜合考慮產品類型、治療分類、分銷管道、給藥途徑、最終用戶、製劑和動物年齡層等因素，可以發現幾種不同的模式。藥品和補充劑是互補的類別；藥品主要用於急性期和疾病特異性干預，而補充劑則廣泛用於預防和長期護理計劃中的結締組織支持。在治療類別中，感染疾病和抗發炎藥物仍然是臨床實踐的核心。在抗感染藥方面，當需要經驗性治療時，應重點使用Aminoglycosides、大環內酯類、青黴素類、磺胺類藥物和四環黴素；而在感染疾病方面，則需要在皮質類固醇策略和非類固醇消炎劑（NSAID）治療之間取得平衡，以控制疼痛和炎症，同時最大限度地降低全身風險。

區域洞察分析美洲、歐洲、中東、非洲和亞太地區馬匹護理市場的需求推動要素、監管差異和商業化策略。

區域趨勢影響需求促進因素、監管預期和商業化策略，但這些影響往往被全球產品團隊低估。在美洲，由於臨床基礎設施相對完善，且集中於大規模獸醫院和專業馬科診所，實證醫學藥物和高階補充劑的推廣應用十分活躍。該地區的臨床方案和支付模式有利於對新型疫苗和生物製藥的投資，而成熟的分銷網路則支持直接向獸醫院和線上藥房管道銷售產品。

從企業觀點強調與競爭對手合作、注重創新、製造策略和夥伴關係模式，這塑造了我們在馬匹治療領域的領導地位。

馬用藥市場的競爭格局呈現出多元化的特點，既有大型動物用藥品公司，也有專業獸藥公司、生技創新企業和藥局。老字型大小企業通常利用其龐大的製造地、豐富的產品系列和全球分銷協議，以支持其產品廣泛滲透到臨床實踐中。雖然這些公司傾向於優先發展實證醫學產品，例如疫苗、循環系統藥物和主要感染疾病物，但它們也會投資於產品生命週期管理和配方改進，以保持其在臨床上的市場地位。

為領導者提供切實可行的、高優先級的建議，以加強馬匹治療領域的供應鏈韌性、擴大臨床證據並最佳化商業化。

產業領導者應推動一系列合作舉措，以增強韌性、加速臨床應用並改善商業性成果。首先，他們應實現供應商網路多元化，並加快原料藥(API) 和成品替代來源的認證，以降低政策衝擊和關稅造成的成本波動風險。同時，他們應優先投資於製劑科學，以簡化給藥流程、提高藥物在各種物流條件下的穩定性，並增強特定年齡層的耐受性，從而提高農場和移動診所等場所使用者的實際用藥依從性。

研究結果得到了透明的混合方法研究途徑結合了相關人員訪談、文獻綜述、細分框架和檢驗方案。

本文提出的見解源自於一項混合方法研究，旨在平衡關鍵相關人員的見解與嚴謹的二手證據。主要資料收集包括對執業獸醫、醫院管理人員、馬場採購經理、製劑科學家和高級銷售主管的結構化訪談，從而獲得關於臨床決策者和營運限制的實地觀點。此外，還透過查閱同行評審的臨床文獻、監管指南、專利申請和公開的臨床試驗註冊信息，補充了這些定性信息，以確保技術準確性並為新興創新提供背景信息。

摘要概述了整個馬匹治療生態系統中相關人員的策略重點、新興風險和機會途徑。

最後，馬用藥品和營養補充劑行業的相關人員必須平衡兩大挑戰：既要提供臨床療效可靠且易於使用的治療方法，又要應對日益複雜的政策和供應鏈環境。在治療重點、不斷變化的經銷管道和區域監管差異的相互作用下，靈活的籌資策略、清晰的臨床證據和適應性強的經營模式至關重要。 2025年的關稅趨勢凸顯了供應鏈多元化和積極遵守貿易法規的必要性，這將推動策略轉型，並在不久的將來影響採購和生產決策。

目錄

第1章 引言

第2章 分析方法

  • 分析設計
  • 分析框架
  • 市場規模預測
  • 數據三角測量
  • 分析結果
  • 分析的前提條件
  • 分析的局限性

第3章執行摘要

  • 首席體驗長的觀點
  • 市場規模和成長趨勢
  • 市佔率分析（2025 年）
  • FPNV定位矩陣（2025）
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入（GTM）策略

第5章 市場洞察

  • 消費者分析與最終用戶觀點
  • 消費者體驗基準測試
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 成本效益分析（ROI）和成本效益分析（CBA）

第6章：美國關稅的累積影響（2025 年）

第7章：人工智慧（AI）的累積影響（2025 年）

第8章：馬用藥品和補充品市場：依產品類型分類

  • 製藥
  • 補充

第9章：馬用藥品和補充品市場：依治療領域分類

  • 麻醉劑
  • 抗感染藥物
    • Aminoglycosides
    • 大環內酯類
    • 青黴素
    • 磺胺類藥物藥物
    • 四環黴素
  • 抗發炎藥
    • 皮質類固醇
    • NSAID
  • 循環系統藥物
  • 消化器官系統藥物
  • 荷爾蒙製劑
  • 神經系統藥物
  • 疫苗

第10章：馬用藥品和補充品市場：依給藥途徑分類

  • 注射藥物
    • 肌肉內部
    • 靜脈
    • 皮下
  • 口服
    • 粉末
    • 糖漿
    • 藥片
  • 外用

第11章：馬用藥品和補充品市場：按劑型分類

  • 奶油
  • 乳液
  • 凝膠
  • 粉末
  • 解決方案
  • 藥片

第12章：馬匹藥品和營養補充品市場：依動物年齡層分類

  • 成年馬
  • 駒
  • 一歲馬（幼駒）

第13章：馬用藥品和補充品市場：依最終用戶分類

  • 馬場
  • 研究機構和學術機構
  • 獸醫診所和上門服務
  • 動物醫院

第14章：馬用藥品和補充品市場：依通路分類

  • 網路藥房
  • 零售藥房
  • 獸醫醫院和診所
  • 獸藥

第15章：馬用藥品和補充品市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第16章：馬用藥品和補充品市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章：馬用藥品和補充品市場：按國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章：美國馬用藥品和補充品市場

第19章：中國馬用藥品和補充品市場

第20章 競爭格局

  • 市場集中度分析（2025 年）
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析（2025 年）
  • 產品系列分析（2025 年）
  • 基準分析（2025 年）
  • AddoVet Ltd.
  • Affinity Petcare SA
  • Alltech Inc.
  • Audevard SAS
  • Bayer Animal Health GmbH
  • Bimeda Inc.
  • Boehringer Ingelheim GmbH & Co. KG
  • CEVA Sante Animale SAS
  • Chanelle Pharma Group Ltd.
  • Dechra Veterinary Products plc
  • Elanco Animal Health Incorporated
  • Hallmarq Veterinary Imaging Ltd.
  • Intas Animal Health Ltd.
  • Kentucky Equine Research LLC
  • Kyoritsu Seiyaku Corporation
  • Lloyd Inc.
  • Merck & Co., Inc.
  • Norbrook Laboratories Ltd.
  • Ouro Fino Saude Animal SA
  • Protexin Healthcare Ltd.
  • Sound Technologies Inc.
  • Vetoquinol SA
  • Virbac SA
  • WF Young Inc.
  • Zoetis Inc.
Product Code: MRR-4348D129FACA

The Equine Pharmaceuticals & Supplements Market was valued at USD 1.03 billion in 2025 and is projected to grow to USD 1.08 billion in 2026, with a CAGR of 6.08%, reaching USD 1.56 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.03 billion
Estimated Year [2026] USD 1.08 billion
Forecast Year [2032] USD 1.56 billion
CAGR (%) 6.08%

A concise orientation to the equine therapeutics landscape highlighting clinical priorities, regulatory responsibilities, and stakeholder expectations across care settings

The equine pharmaceuticals and supplements domain demands a focused orientation that balances clinical need, regulatory oversight, and commercial practicality. Increasingly complex therapeutic regimens, diversified end users, and a broader array of delivery formats have combined to create a landscape where precision, safety, and supply reliability are paramount. Veterinarians and farm managers require products that deliver predictable outcomes across adult horses, foals, and yearlings, while research institutions and hospitals prioritize evidence-backed formulations and robust adverse event monitoring.

Across product distinctions, pharmaceuticals continue to anchor acute care and disease-specific treatments, while supplements are often deployed for preventive care, performance support, and long-term musculoskeletal health. Meanwhile, distribution has broadened beyond traditional veterinary pharmacies to include online pharmacies and integrated hospital channels, introducing new considerations around cold-chain management, authentication, and regulatory compliance. Transitioning from concept to clinic also involves navigating evolving therapeutic categories such as anti-infectives and anti-inflammatories, where formulation and route of administration materially impact clinical adoption.

Taken together, these dynamics require strategic alignment across R&D, manufacturing, regulatory affairs, and commercial teams. By foregrounding clinical utility, safety, and distribution integrity, stakeholders can better prioritize investments and interventions that deliver measurable value in equine care settings.

How technological innovation, regulatory modernization, and evolving veterinary care models are fundamentally altering product development and delivery in equine therapeutics

The equine therapeutics landscape is being reshaped by multiple intersecting forces that are altering how products are developed, validated, and delivered. Advances in biologics and vaccine platforms are enabling more targeted preventive approaches, even as antimicrobial stewardship imperatives push formulators and prescribers toward refined anti-infective strategies and alternative supportive modalities. Concurrently, digital health tools and telemedicine are changing the cadence of veterinary consultations and enabling remote monitoring, which affects how products are prescribed and how adherence is tracked.

Supply chain and manufacturing practices are also evolving. Contract manufacturing and regional production hubs are gaining traction as companies seek to shorten lead times and reduce reliance on single-source active pharmaceutical ingredient suppliers. At the same time, e-commerce and direct-to-practice distribution channels are forcing companies to rethink packaging, serialization, and cold-chain protocols to maintain product integrity and regulatory traceability. These shifts are complemented by a heightened focus on formulation science, where innovations in topical gels, oral powders, and injectable presentations are improving bioavailability and user convenience.

Together, these transformations create opportunities for differentiated value propositions, but they also impose new requirements for cross-functional coordination. Firms that align clinical evidence generation with flexible manufacturing, digital-enabled distribution, and clear regulatory strategies will be better positioned to translate innovation into commercial and clinical impact.

Assessing the multifaceted operational, clinical, and strategic consequences of the United States tariff measures introduced in 2025 on the equine therapeutics value chain

The 2025 tariff measures introduced by the United States have had a material and multifaceted influence on the operational and strategic calculus of organizations involved in equine pharmaceuticals and supplements. Cost structures for imported active ingredients and finished goods were directly affected, prompting procurement teams to reassess supplier portfolios and to accelerate qualification of alternative sources. In practice, this has meant a stronger emphasis on regional sourcing, inventory buffering, and in some cases, reshoring or nearshoring of critical manufacturing steps to mitigate future policy risk.

Beyond procurement, distribution patterns shifted as companies rebalanced logistics to minimize tariff exposure. This rebalancing increased demand for contract manufacturers and third-party logistics providers with cross-border capabilities, and it elevated the importance of tariff classification, origin documentation, and trade compliance expertise within commercial operations. Smaller manufacturers and specialized compounding pharmacies felt disproportionate pressure, as they typically have less flexibility to absorb cost shocks or negotiate bulk purchase discounts.

Clinically, the tariff environment translated into tighter price negotiations with veterinary customers and a renewed focus on demonstrating cost-effectiveness and therapeutic differentiation. As a result, product teams prioritized investments that enhanced formulation efficiency, extended shelf life, or enabled lower-cost routes of administration. From a strategic perspective, the tariffs catalyzed a broader industry reassessment of supply chain resilience, corporate tax planning, and the merits of localized manufacturing footprints versus a globally optimized but policy-exposed supply chain.

Actionable segmentation intelligence revealing how product types, therapeutic classes, distribution channels, administration routes, end users, formulations, and age groups inform clinical adoption

Segmentation offers the most direct route to actionable differentiation in equine therapeutics, and several clear patterns emerge when product type, therapeutic class, distribution, route of administration, end user, formulation, and animal age group are considered together. Pharmaceuticals and supplements function as complementary categories; pharmaceuticals are prioritized for acute and disease-specific interventions, while supplements are more commonly adopted for preventive and connective tissue support across long-term care plans. Within therapeutic categories, anti-infectives and anti-inflammatories remain core pillars of clinical practice, with anti-infectives emphasizing agents such as aminoglycosides, macrolides, penicillins, sulfonamides, and tetracyclines when empirical coverage is needed, and anti-inflammatories balancing corticosteroid strategies against NSAID regimens to manage pain and inflammation while minimizing systemic risk.

Distribution preferences are shifting as veterinarians and hospitals increasingly source through online pharmacies and integrated veterinary hospital channels, reducing friction for repeat prescriptions and enabling better adherence tracking. Injectable presentations continue to be essential for many acute and inpatient interventions, with intramuscular, intravenous, and subcutaneous options selected based on onset requirements and tolerability. Oral forms, particularly powders, syrups, and tablets, are favored for outpatient management and for foals where palatability and dosing precision are critical. Topical formulations, including creams, emulsions, and gels, offer targeted local therapy that reduces systemic exposure and supports recovery in musculoskeletal and dermatological conditions.

End-user segmentation reveals that equine farms and veterinary hospitals are primary purchasers of high-value therapeutic products, whereas research institutions and ambulatory services increasingly influence early adoption of novel biologics and vaccines. Formulation choices must therefore reconcile handling preferences of field practitioners with the stability demands of hospital pharmacies. Moreover, age-group considerations are integral to product positioning: adult horses often require chronic management solutions focused on musculoskeletal health and cardiovascular support, foals demand gentler oral and injectables with careful dosing, and yearlings fall into a transitional category where both preventive supplements and standard pharmaceuticals are commonly used. By integrating these segmentation dimensions, product teams can better align development priorities with user workflows and clinical decision-making criteria.

Regional intelligence unpacking demand drivers, regulatory variation, and commercialization strategies across the Americas, EMEA, and Asia-Pacific equine care markets

Regional dynamics shape demand drivers, regulatory expectations, and commercialization strategies in ways that are often underappreciated by global product teams. In the Americas, clinical infrastructures are relatively advanced and concentrated in high-volume veterinary hospitals and specialist equine clinics, yielding strong uptake of evidence-backed pharmaceuticals and premium supplements. Clinical protocols and payer models in this region encourage investment in novel vaccines and biologics, and the presence of well-established distribution networks supports both direct-to-practice and online pharmacy channels.

In Europe, Middle East and Africa, regulatory heterogeneity and differing farm structures create a mosaic of commercial approaches. European markets emphasize stringent pharmacovigilance and antimicrobial stewardship, which affects labeling, usage guidance, and the acceptability of certain systemic agents. Middle Eastern and African subregions introduce additional complexity with variations in import logistics, cold-chain infrastructure, and localized disease pressure, all of which influence product prioritization and go-to-market tactics.

Asia-Pacific presents a distinct mix of rapid adoption in urban veterinary centers and growing demand from emerging equine leisure and sport segments. Manufacturing capacity and ingredient sourcing in the region can be advantageous for supply continuity, yet regulatory frameworks and import practices vary considerably from market to market. Across all regions, trade policies and tariff dynamics continue to exert influence on sourcing decisions, and companies that craft region-specific regulatory filings, distribution partnerships, and pricing strategies will be better positioned to capture the full spectrum of demand.

Competitive and collaborative company-level perspectives emphasizing innovation focus, manufacturing strategy, and partnership models shaping equine therapeutics leadership

Competitive landscapes in equine therapeutics are characterized by a mixture of large animal health companies, specialized veterinary pharmaceutical firms, biotech innovators, and compounding pharmacies. Established firms often leverage broad manufacturing footprints, diversified portfolios, and global distribution agreements to support widespread clinical penetration. They tend to prioritize high-evidence products such as vaccines, cardiovascular agents, and key anti-infectives, while also investing in lifecycle management and formulation improvements to retain clinical preference.

Specialist players and biotech entrants are differentiating through targeted innovation, such as next-generation biologics, improved analgesic modalities, and formulation science that enhances bioavailability or reduces administration frequency. These firms frequently pursue strategic partnerships with research institutions and veterinary hospitals to accelerate clinical validation and to access early-adopter cohorts. Contract manufacturing organizations and third-party logistics providers are increasingly central to competitive positioning, enabling faster market entry and flexible scaling while allowing companies to control capital expenditure.

Across the competitive set, successful strategies include clear articulation of clinical value, robust regulatory dossiers, and integrated commercial models that combine direct engagement with veterinarians, digital education platforms, and efficient distribution. Firms that can demonstrate reproducible clinical outcomes, secure supply chain resilience, and offer effective support services for end users will generally achieve stronger market traction and more durable customer relationships.

Practical and prioritized recommendations for leaders to reinforce supply resilience, amplify clinical evidence, and optimize commercialization in equine therapies

Industry leaders should pursue a coordinated set of actions that enhance resilience, accelerate clinical adoption, and improve commercial outcomes. First, diversify supplier networks and accelerate qualification of alternative API and finished-goods sources to reduce exposure to policy shocks and tariff-driven cost volatility. Concurrently, prioritize investments in formulation science that lower administration complexity, improve stability under varied logistics conditions, and address specific age-group tolerability, thereby increasing real-world adherence among farm-based and ambulatory users.

Second, deepen engagement with veterinary stakeholders through targeted clinical evidence generation and practitioner-focused education programs. Generating pragmatic clinical data that highlights cost-effectiveness, safety, and ease of administration will support uptake among hospitals, clinics, and farm managers. Third, optimize distribution by combining direct-to-practice models with validated online pharmacy channels, ensuring serialization and traceability to preserve product integrity and combat counterfeiting.

Fourth, prepare regulatory and trade-compliance strategies that anticipate tariff shifts and heterogeneous regional requirements. Building capabilities in tariff classification, origin documentation, and regulatory harmonization will accelerate market access and reduce time-to-shelf. Finally, explore collaborative ventures with contract manufacturers, research institutions, and technology providers to share risk, accelerate innovation, and create bundled service offerings that enhance practitioner value propositions. These coordinated measures will support sustainable growth while managing near-term operational exposure.

Transparent mixed-methods research approach combining stakeholder interviews, literature review, segmentation frameworks, and validation protocols to underpin findings

The findings presented here are derived from a mixed-methods research approach designed to balance primary stakeholder insight with rigorous secondary evidence. Primary data collection included structured interviews with practicing veterinarians, hospital administrators, procurement leads at equine farms, formulation scientists, and senior commercial executives, providing frontline perspectives on clinical decision drivers and operational constraints. These qualitative inputs were complemented by a review of peer-reviewed clinical literature, regulatory guidance, patent filings, and publicly available clinical trial registries to ensure technical accuracy and to contextualize emergent innovations.

Analytical frameworks employed include segmentation analysis across product type, therapeutic category, distribution channel, route of administration, end user, formulation, and age group, as well as scenario planning to evaluate policy and supply chain contingencies. Triangulation was used at multiple stages to validate insights, combining interview evidence with secondary documentation and cross-regional trade data. An expert panel review provided an additional layer of validation, focusing on clinical plausibility and commercial relevance. Limitations include regional variation in data availability and the evolving nature of policy interventions that may change the competitive environment; where appropriate, assumptions and confidence levels are documented in the methodology annex to aid interpretation.

Concluding synthesis crystallizing strategic priorities, emergent risks, and opportunity pathways for stakeholders across the equine therapeutics ecosystem

In closing, stakeholders operating in the equine pharmaceuticals and supplements sector must reconcile a dual imperative: deliver clinically robust, user-friendly therapies while managing an increasingly complex policy and supply chain environment. The interplay of therapeutic priorities, distribution channel evolution, and regional regulatory variation requires nimble sourcing strategies, clear clinical evidence, and adaptive commercial models. Tariff dynamics introduced in 2025 have underscored the necessity of supply chain diversification and proactive trade compliance, catalyzing strategic shifts that will influence sourcing and manufacturing decisions for the foreseeable future.

Equally important is the need to align product development with real-world veterinary workflows and age-specific dosing considerations, ensuring that formulations meet the practical demands of equine farms, ambulatory services, research institutions, and hospitals. Organizations that integrate rigorous clinical validation with flexible manufacturing arrangements and targeted regional strategies will be best placed to capture sustained value. Ultimately, the most successful participants will be those that translate technical innovation into clear practitioner benefits while maintaining operational resilience against external shocks.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Equine Pharmaceuticals & Supplements Market, by Product Type

  • 8.1. Pharmaceuticals
  • 8.2. Supplements

9. Equine Pharmaceuticals & Supplements Market, by Therapeutic Category

  • 9.1. Anesthetic Agents
  • 9.2. Anti-Infectives
    • 9.2.1. Aminoglycosides
    • 9.2.2. Macrolides
    • 9.2.3. Penicillins
    • 9.2.4. Sulfonamides
    • 9.2.5. Tetracyclines
  • 9.3. Anti-Inflammatories
    • 9.3.1. Corticosteroids
    • 9.3.2. NSAIDs
  • 9.4. Cardiovascular Agents
  • 9.5. Gastrointestinal Agents
  • 9.6. Hormonal Preparations
  • 9.7. Nervous System Agents
  • 9.8. Vaccines

10. Equine Pharmaceuticals & Supplements Market, by Route Of Administration

  • 10.1. Injectable
    • 10.1.1. Intramuscular
    • 10.1.2. Intravenous
    • 10.1.3. Subcutaneous
  • 10.2. Oral
    • 10.2.1. Powders
    • 10.2.2. Syrups
    • 10.2.3. Tablets
  • 10.3. Topical

11. Equine Pharmaceuticals & Supplements Market, by Formulation

  • 11.1. Creams
  • 11.2. Emulsions
  • 11.3. Gels
  • 11.4. Powders
  • 11.5. Solutions
  • 11.6. Tablets

12. Equine Pharmaceuticals & Supplements Market, by Animal Age Group

  • 12.1. Adult Horses
  • 12.2. Foals
  • 12.3. Yearlings

13. Equine Pharmaceuticals & Supplements Market, by End User

  • 13.1. Equine Farms
  • 13.2. Research Institutions & Academics
  • 13.3. Veterinary Clinics & Ambulatory Services
  • 13.4. Veterinary Hospitals

14. Equine Pharmaceuticals & Supplements Market, by Distribution Channel

  • 14.1. Online Pharmacies
  • 14.2. Retail Pharmacies
  • 14.3. Veterinary Hospitals & Clinics
  • 14.4. Veterinary Pharmacies

15. Equine Pharmaceuticals & Supplements Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Equine Pharmaceuticals & Supplements Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Equine Pharmaceuticals & Supplements Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Equine Pharmaceuticals & Supplements Market

19. China Equine Pharmaceuticals & Supplements Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. AddoVet Ltd.
  • 20.6. Affinity Petcare SA
  • 20.7. Alltech Inc.
  • 20.8. Audevard SAS
  • 20.9. Bayer Animal Health GmbH
  • 20.10. Bimeda Inc.
  • 20.11. Boehringer Ingelheim GmbH & Co. KG
  • 20.12. CEVA Sante Animale SAS
  • 20.13. Chanelle Pharma Group Ltd.
  • 20.14. Dechra Veterinary Products plc
  • 20.15. Elanco Animal Health Incorporated
  • 20.16. Hallmarq Veterinary Imaging Ltd.
  • 20.17. Intas Animal Health Ltd.
  • 20.18. Kentucky Equine Research LLC
  • 20.19. Kyoritsu Seiyaku Corporation
  • 20.20. Lloyd Inc.
  • 20.21. Merck & Co., Inc.
  • 20.22. Norbrook Laboratories Ltd.
  • 20.23. Ouro Fino Saude Animal S.A.
  • 20.24. Protexin Healthcare Ltd.
  • 20.25. Sound Technologies Inc.
  • 20.26. Vetoquinol SA
  • 20.27. Virbac SA
  • 20.28. W.F. Young Inc.
  • 20.29. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY THERAPEUTIC CATEGORY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANIMAL AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SUPPLEMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SUPPLEMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SUPPLEMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANESTHETIC AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANESTHETIC AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANESTHETIC AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFECTIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFECTIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFECTIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY AMINOGLYCOSIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY AMINOGLYCOSIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY MACROLIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PENICILLINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PENICILLINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PENICILLINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SULFONAMIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SULFONAMIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SULFONAMIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFLAMMATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFLAMMATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFLAMMATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY NSAIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY NSAIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY NSAIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY CARDIOVASCULAR AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY CARDIOVASCULAR AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY CARDIOVASCULAR AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY GASTROINTESTINAL AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY GASTROINTESTINAL AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY GASTROINTESTINAL AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY HORMONAL PREPARATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY HORMONAL PREPARATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY HORMONAL PREPARATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY NERVOUS SYSTEM AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY NERVOUS SYSTEM AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY NERVOUS SYSTEM AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY POWDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY POWDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY POWDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SYRUPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SYRUPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SYRUPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY CREAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY CREAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY CREAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY EMULSIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY EMULSIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY EMULSIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY GELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY GELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY GELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY POWDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY POWDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY POWDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SOLUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SOLUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SOLUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ADULT HORSES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ADULT HORSES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ADULT HORSES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY FOALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY FOALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY FOALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY YEARLINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY YEARLINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY YEARLINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY EQUINE FARMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY EQUINE FARMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY EQUINE FARMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY RESEARCH INSTITUTIONS & ACADEMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY RESEARCH INSTITUTIONS & ACADEMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY RESEARCH INSTITUTIONS & ACADEMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY CLINICS & AMBULATORY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY CLINICS & AMBULATORY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY CLINICS & AMBULATORY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 147. AMERICAS EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 148. AMERICAS EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 149. AMERICAS EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 150. AMERICAS EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 151. AMERICAS EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 152. AMERICAS EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. AMERICAS EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. AMERICAS EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 208. MIDDLE EAST EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 220. AFRICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 221. AFRICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 222. AFRICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 223. AFRICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 224. AFRICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 225. AFRICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. AFRICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 239. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. ASEAN EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. ASEAN EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 243. ASEAN EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 244. ASEAN EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 245. ASEAN EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 246. ASEAN EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 247. ASEAN EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 248. ASEAN EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 249. ASEAN EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 250. ASEAN EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 251. ASEAN EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 252. GCC EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 253. GCC EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. GCC EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 255. GCC EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 256. GCC EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 257. GCC EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 258. GCC EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 259. GCC EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 260. GCC EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 261. GCC EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 262. GCC EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 263. GCC EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPEAN UNION EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPEAN UNION EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPEAN UNION EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPEAN UNION EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 273. EUROPEAN UNION EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 274. EUROPEAN UNION EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 277. BRICS EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. BRICS EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 279. BRICS EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY